Pharmaceutical companies Innova Captab Ltd and Blue Jet Healthcare have received Sebi's go-ahead to raise funds through initial public offering (IPO).
The two firms, which filed their preliminary papers with Sebi between June and September 2022, obtained its observation letters during January 9-11, an update with Sebi showed on Tuesday.
In Sebi's parlance, its observation implies its go-ahead to launch the initial share-sale.
As per the draft papers, Innova Captab's proposed IPO comprises fresh issuance of equity shares worth Rs 400 crore and an offer for sale (OFS) of 96 lakh equity shares by promoters and other shareholders.
Under the OFS, Manoj Kumar Lohariwala, Vinay Kumar Lohariwala and Gian Parkash Aggarwal will sell 32 lakh shares each.
Of the Rs 400 crore proposed to be raised through fresh issuance of equity shares, Rs 180.5 crore will be used for payment of debt, Rs 29.5 crore for payment of loans availed by its subsidiary UML, and Rs 90 crore for funding working capital requirements.
Toyota Motor's new Innova HyCross priced at Rs 18.30 lakh onwards
Jet airways revival hits new snag as banks push back on funding
Twitter Blue 'verification' rolled out in India, to cost Rs 719 per month
Blue Jet Healthcare files draft papers with Sebi for Rs 2,100-cr IPO
Indian pharma sector set for 'volume to value leadership' journey in 2023
From Paytm to Zomato, start-ups see fresh round of selling; stock falls
Equity benchmarks defy global cues, finish nearly 1% in the green
Berger Paints India eyes Rs 20,000 crore turnover in the next 5-6 years
Shift of axis from Indian markets: FPIs pivot to China as it unlocks
Sebi moots ASBA-like payment system for secondary market stock trade
Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports.
The IPO of pharmaceutical ingredients maker Blue Jet Healthcare is completely an OFS of up to 21,683,178 equity shares by promoters Akshay Bansarilal Arora and Shiven Akshay Arora.
The Mumbai-based firm offers niche products targeted toward innovator pharmaceutical companies and multinational generic pharmaceutical companies.
Shares of both companies will be listed on the stock exchanges -- BSE and NSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)